Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 2
1996 4
1997 2
1998 2
1999 6
2000 7
2001 3
2002 5
2003 10
2004 16
2005 10
2006 10
2007 11
2008 14
2009 21
2010 25
2011 27
2012 36
2013 31
2014 31
2015 21
2016 27
2017 21
2018 26
2019 18
2020 17
2021 22
2022 14
2023 22
2024 18
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax Resistance in Acute Myeloid Leukemia.
Garciaz S, Hospital MA, Collette Y, Vey N. Garciaz S, et al. Among authors: vey n. Cancers (Basel). 2024 Mar 8;16(6):1091. doi: 10.3390/cancers16061091. Cancers (Basel). 2024. PMID: 38539426 Free PMC article. Review.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Fenaux P, et al. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. Lancet Oncol. 2009. PMID: 19230772 Free PMC article. Clinical Trial.
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.
Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL). Huguet F, et al. Among authors: vey n. J Clin Oncol. 2018 Aug 20;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192. Epub 2018 Jun 4. J Clin Oncol. 2018. PMID: 29863974 Free article. Clinical Trial.
Erythroleukemia: Classification.
Cervera N, Guille A, Adélaïde J, Hospital MA, Garciaz S, Mozziconacci MJ, Vey N, Gelsi-Boyer V, Birnbaum D. Cervera N, et al. Among authors: vey n. EJHaem. 2023 Mar 17;4(2):450-453. doi: 10.1002/jha2.676. eCollection 2023 May. EJHaem. 2023. PMID: 37206278 Free PMC article.
[Myelodysplastic syndromes].
Garciaz S, Vey N. Garciaz S, et al. Among authors: vey n. Rev Prat. 2023 Feb;73(2):221-226. Rev Prat. 2023. PMID: 36916268 French. No abstract available.
Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Hunault M, Pautas C, Bertoli S, Dumas PY, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie S, Carré M, Peterlin P, Gallego-Hernanz MP, Lemasle E, Guièze R, Simand C, Turlure P, Huynh A, Leguay T, Devillier R, Quoc SN, Duployez N, Luquet I, Penther D, Celli-Lebras K, Mineur A, Raus N, Gardin C, Socié G, Cahn JY, Ifrah N, Vey N, de Latour RP, Delabesse E, Preudhomme C, Hamel JF, Pigneux A, Récher C, Dombret H. Hunault M, et al. Among authors: vey n. NEJM Evid. 2025 Jul;4(7):EVIDoa2400326. doi: 10.1056/EVIDoa2400326. Epub 2025 Jun 24. NEJM Evid. 2025. PMID: 40552969 Clinical Trial.
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.
Stuani L, Sabatier M, Saland E, Cognet G, Poupin N, Bosc C, Castelli FA, Gales L, Turtoi E, Montersino C, Farge T, Boet E, Broin N, Larrue C, Baran N, Cissé MY, Conti M, Loric S, Kaoma T, Hucteau A, Zavoriti A, Sahal A, Mouchel PL, Gotanègre M, Cassan C, Fernando L, Wang F, Hosseini M, Chu-Van E, Le Cam L, Carroll M, Selak MA, Vey N, Castellano R, Fenaille F, Turtoi A, Cazals G, Bories P, Gibon Y, Nicolay B, Ronseaux S, Marszalek JR, Takahashi K, DiNardo CD, Konopleva M, Pancaldi V, Collette Y, Bellvert F, Jourdan F, Linares LK, Récher C, Portais JC, Sarry JE. Stuani L, et al. Among authors: vey n. J Exp Med. 2021 May 3;218(5):e20200924. doi: 10.1084/jem.20200924. J Exp Med. 2021. PMID: 33760042 Free PMC article.
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Venditti A, Palmieri R, Maurillo L, Röllig C, Wierzbowska A, de Leeuw D, Efficace F, Curti A, Ngai LL, Tettero J, Adès L, Almeida A, Bullinger L, Dennis M, Esteve J, Ferrara F, Heuser M, Huls G, Lübbert M, Mehta P, Montesinos P, Pabst T, Récher C, Rossi G, Russell N, Sierra J, Stauder R, Vey N, Walter RB, Wang E, Nier S, Martins CG, Ossenkoppele G. Venditti A, et al. Among authors: vey n. Blood Adv. 2025 May 13;9(9):2207-2220. doi: 10.1182/bloodadvances.2024013744. Blood Adv. 2025. PMID: 39913928 Free PMC article. Review.
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Chiche E, Rahmé R, Bertoli S, Dumas PY, Micol JB, Hicheri Y, Pasquier F, Peterlin P, Chevallier P, Thomas X, Loschi M, Genthon A, Legrand O, Mohty M, Raffoux E, Auberger P, Caulier A, Joris M, Bonmati C, Roth-Guepin G, Lejeune C, Pigneux A, Vey N, Recher C, Ades L, Cluzeau T. Chiche E, et al. Among authors: vey n. Blood Adv. 2021 Jan 12;5(1):176-184. doi: 10.1182/bloodadvances.2020003159. Blood Adv. 2021. PMID: 33570629 Free PMC article.
411 results